Olerup SSP ready for the US

Published: 2009-09-15

Olerup SSP has had its Taq-polymerase-free HLA typing kit registered and cleared by the FDA. This means that Olerup SSP´s entire product range for HLA typing, with or without Taq polymerase, can now be marketed and sold to a greater number of healthcare centers in North America. The U.S. is the single largest market for HLA typing and represents over 40 percent of the global tissue typing market. Olerup SSP´s HLA typing kit with Taq polymerase has been approved by the FDA for sale in the United States since March 2009.

About Olerup:

Olerup SSP is the world leader in the development of kits for genomic HLA typing, which is used prior to transplantations to match donors with recipients. Better matching reduces the risk of complications following transplantation. HLA typing is a standard procedure in bone marrow transplantation (hematopoietic stem cell transplantation) but is also used in organ transplantations (kidney, lung, heart, and others).

Olerup SSP had sales of SEK 43 million for the period January to June 2009 and reported an EBIT profit of SEK 25 million. The company was founded in 1992 by Professor Olle Olerup and has a total of 23 employees. Since July 2008, Olerup SSP is 100 percent owned by LinkMed.